Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study.

Journal of Oncology
V SurmontR J van Klaveren

Abstract

Background. sequential chemotherapy can maintain dose intensity and preclude cumulative toxicity by increasing drug diversity. Purpose. to investigate the toxicity and efficacy of the sequential regimen of gemcitabine followed by paclitaxel in first line advanced stage non-small cell lung cancer (NSCLC) patients with good performance status (PS). Patients and methods. gemcitabine 1250 mg/m(2) was administered on day 1 and 8 of course 1 and 2; Paclitaxel 150 mg/m(2) on day 1 and 8 of course 3 and 4. Primary endpoint was response rate (RR), secondary endpoints toxicity and time to progression (TTP). Results. Of the 21 patients (median age 56, range 38-80 years; 62% males, 38% females) 10% (2/21) had stage IIIB, 90% (19/21) stage IV, 15% PS 0, 85% PS 1. 20% of patients had a partial response, 30% stable disease, 50% progressive disease. Median TTP was 12 weeks (range 6-52 weeks), median overall survival (OS) 8 months (range 1-27 months), 1-year survival was 33%. One patient had grade 3 hematological toxicity, 2 patients a grade 3 peripheral neuropathy. Conclusions. sequential administration of gemcitabine followed by paclitaxel in first line treatment of advanced NSCLC had a favourable toxicity profile, a median TTP and OS compara...Continue Reading

References

Dec 1, 1994·Klinische Monatsblätter für Augenheilkunde·H Mittelviefhaus
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W AkerleyL Leone
May 16, 2000·Chest·D J Barnes
Oct 24, 2000·Biology of the Cell·A McDougallM Whitaker
Oct 27, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J I ClarkK S Albain
Jan 5, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J FeliuUNKNOWN Oncopaz Cooperative Group, Spain
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Jul 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank FossellaChandra P Belani
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin J EdelmanDavid R Gandara
Oct 7, 2004·Japanese Journal of Clinical Oncology·Junko KikuchiMasaharu Nishimura
Feb 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giannicola D'AddarioFrances A Shepherd
May 5, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Hideo K TakahashiNoriaki Tanaka
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christer SederholmSulochana R Gawande
Sep 8, 2006·The New England Journal of Medicine·Ken A OlaussenUNKNOWN IALT Bio Investigators
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George SimonGerold Bepler
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manuel CoboRafael Rosell
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Panos M FidiasJoan H Schiller
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J Gallagher, Nancy E Kemeny

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.